North America Pharmacogenetics Testing in Psychiatry Depression Market Intelligence Reports Benchmarking report Forecast 2029
North America pharmacogenetics testing in psychiatry/depression market is expected to reach the value of USD 981.28 million by 2029, at a CAGR of 9.7% during the forecast period. Anxiety accounts for the largest type segment in the market due to the increasing depression rate among the North American population.
By employing definite steps to collect, record, and analyse market data, the...
0 Reacties
0 aandelen
413 Views